News
AstraZeneca’s Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern
Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health Research, published...
News
Labcorp To Offer First And FDA-Cleared Test For Monitoring Residual Blood Cancer Cells During And After Treatme
Labcorp, a leading global life sciences company, announced that it is now offering clonoSEQ®, the first U.S. Food and Drug Administration (FDA)-cleared test that...
News
AstraZeneca Small-Cell Lung Cancer Treatment Imfinzi Approved in China
AstraZeneca PLC said that its Imfinzi immunotherapy treatment for extensive-stage small-cell lung cancer has been approved in China for first-line treatment of adult patients,...
News
Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer enabled therapeutics
Aptamer Group, the developer of Optimer therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, announce a...
Articles
Vaccine Temperatures: Keeping it cool for COVID-19
With more vaccines being approved worldwide, maintaining the shipments’ integrity throughout the delivery process is the most challenging hurdle for many logistics providers.
Since the...
News
Top Industrialization Challenges of Gene Therapy Manufacturing
Manufacturing and scale-up of industrialized processes to manufacture gene therapy products are accompanied by many challenges that must be overcome to succeed in the...
Press Releases
ISR signs agreement with Singapore Resources Dev regarding investment in subsidiaries for the development of inhaled COVID-19 vaccine
ISR Immune System Regulation Holding AB (publ), which develops inhalation vaccine against Covid-19, today announced that it has signed an investment agreement with Singapore...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read